Introduction
Juvenile myoclonic epilepsy (JME) is a well defined and distinct clinical syndrome from other idiopathic generalized epilepsy (IGE) syndromes. 1 It is the most common form of IGE accounting for up 26% of patients with IGEs and up to 10% of patients with epilepsy. 2 It is most likely to start at puberty or late teenage years. 3 The hallmark of the syndrome is myoclonic seizures, mainly involving arms and upper body during post-awakening period. 2, 4 Generalized tonic clonic seizures occur in most patients and are often precipitated by sleep deprivation, stress, alcohol and hypoglycemia. 2, 4 One third of the patients experience absence seizures. 5 Electrographically, patients have a normal background with interictal spike-wave and polyspike-wave discharges. Although the repetition rate is usually higher than 3 Hz (most commonly 3.5-6 Hz), a variable range of 2-10 Hz have been reported. 6 27-41% of patients demonstrate photosensitivity. 6 About 80-90% of patients with JME respond to appropriate antiepileptic treatment and achieve seizure freedom, 4 and about 15% of patients become intractable. 7 The historical gold standard for treatment of JME is valproic acid (VPA), which is considered the most efficacious drug for treatment of this disorder. 8 However, some patients may experience poor tolerability due to dosedependent side effects of tremor, alopecia, weight gain, and secondary amenorrhea, or rare idiosyncratic reactions. 9 Additionally VPA has teratogenic effects with approximately three-fold increase in the rate of major anomalies and it is best avoided when possible. 10, 11 Juvenile myoclonic epilepsy is the most common form of idiopathic generalized epilepsy with onset at puberty or late teenage years. About 80-90% of patients with juvenile myoclonic epilepsy respond to appropriate antiepileptic treatment and achieve seizure freedom, and about 15% of patients become intractable. Valproic acid, levetiracetam, lamotrigine, topiramate and zonisamide are used as first line or adjunctive therapy of this disorder. Lacosamide is approved for adjunctive treatment of partial onset epilepsies. The role of lacosamide in treatment of idiopathic generalized epilepsy including juvenile myoclonic epilepsy is unknown. We present three patients with classic clinical and electrographic features of juvenile myoclonic epilepsy that were maintained on lacosamide (one on monotherapy and two as adjuvant therapy). There were no special pharmacodynamic actions causing exacerbation or worsening of myoclonic jerks or generalized seizures in these three patients. In conclusion, although, the data from our three patients' suggest that lacosamide may be effective in the treatment of juvenile myoclonic epilepsy, larger studies are needed to explore efficacy and role of lacosamide in the treatment of this disorder. ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. JME in whom lacosamide therapy was used either as first line or adjunctive therapy.
Cases
The following three cases were referred to the University of Utah Comprehensive Epilepsy Clinic for evaluation and treatment of their seizures.
Case 1 is a 19 year old right-handed lady with onset of myoclonic jerks at 14 years of age shortly followed by development of generalized tonic-clonic seizures. She was cognitively normal and there was no reported history of learning disabilities. Her inter-ictal EEG showed 4-6 Hz high amplitude polyspike and slow waves and her MRI was normal. Her seizures have always been easily controlled on VPA, but she complained of mental slowing, mood and behavioral side effects on VPA. Therefore she was tried on other antiepileptic medications. She experienced a severe rash on LTG. She had anywhere from one to four seizures per month on LEV up to a dosage of 6 g per day (serum level of 74). When her TPM titration reached a dosage of 100 mg per day, she experienced paresthesias and declined to stay on TPM, despite counseling about the benign nature of paresthesias. She was then started on lacosamide monotherapy and was titrated up to 400 mg per day. She was seizure free on lacosamide monotherapy on 200 mg PO BID for 6 months, at which point despite extensive counseling about the natural history of JME and lifelong necessity for AED treatment, she decided to self discontinue her medication. One week after self discontinuation she had four generalized tonic clonic seizures in one day, following which she restarted her medication, and she has now been seizure free for twelve months on 400 mg/day of lacosamide and serum levels of 12-16. It is presumed that the fluctuation in her lacosamide level is due to irregularities in her medication intake.
Case 2 is 19 year old left-handed/ambidextrous man with seizure onset at age 15. He reported experiencing absence seizure, myoclonic jerks and generalized tonic-clonic seizures. He was cognitively normal and there was no reported history of learning disabilities. He reported positive family history of primary generalized epilepsy (syndromic classification not known) in his maternal cousin. His MRI was normal, and his interictal EEG showed 3-4 Hz spike and slow waves as well as photoconvulsive response. His seizure frequency (generalized tonic-clonic seizures) was reported to be about one seizure every 6 weeks during periods of mono-therapy, initially with LTG followed by VPA monotherapy. At the time of his referral to epilepsy clinic he was on monotherapy with the extended release formulation of VPA (with mildly supra therapeutic serum level of 104) and was experiencing 1-2 breakthrough generalized seizures per year. He reported occasional myoclonic jerks, mainly affecting his arms and shoulders. During times of physical stress (playing hockey or exertion) he has intermittent episodes of staring (lasting 5-10 s). He was unable to report their true frequency. It was decided to add a second agent to his antiepileptic regimen. He did not want to start ZNS or TPM due to their cognitive side effects and he decided not to start LEV due to its mood side effects. Lacosamide was added to his extendedrelease VPA and was titrated up to 150 mg PO BID. He had no generalized seizures for six months on dual therapy with extended-release VPA and lacosamide 150 mg PO BID (with levels of 9.2), but continued to experience occasional early AM myoclonic jerks. His absences were shorter in duration (perceived by patient to last a second or a fraction of a second). Therefore his lacosamide was titrated up to 200 BID. This abated the myoclonic jerks and absences. He has been seizure free for 18 months.
Case 3 is a 23-year old right handed lady with seizure onset at age 15. Her first seizure started with a prolonged period of twitching that ended in a generalized tonic-clonic seizure.
Retrospectively she had experienced isolated myoclonic jerks on awakening, but she was not certain of when they started. Her MRI was normal and her inter-ictal EEG showed diffuse poly-spike and slow waves, as well as 2.5-4 Hz spike and slow waves. She was started on VPA and became seizure free but experienced mood and behavioral side effects. At age 17 she was changed to LTG and maintained seizure freedom for two years. At age 19 during a period of sleep deprivation, she experienced a single generalized seizure on LTG. At age 20 she had a second break through seizure at 7th month of pregnancy. LEV at 500 mg PO BID was added to her regimen, and she maintained seizure freedom throughout the rest of her pregnancy, but experienced mood and behavioral side effects. Postpartum, LEV was tapered and discontinued resulting in another generalized seizure and therefore LEV 500 mg PO BID was restarted again and her LTG was continued.
She was referred to epilepsy clinic in her postpartum period on dual therapy with LEV and LTG. She was experiencing intermittent myoclonic jerks and about one generalized seizure every 4-6 weeks on this regimen. Patient had past medical history and family history of kidney stones and therefore it was decided to avoid TPM and ZNG. Lacosamide was added to her regimen and titrated to 200 mg PO BID and her lamictal was tapered and discontinued to avoid additive sodium channel blocking side effects. She became seizure free on dual therapy with LEV and lacosamide, but experienced side effects of fatigue, depression, and anxiety. Therefore after four months of seizure freedom her regimen was changed back to LTG 200 mg PO BID and higher dosages of LEV (1000 mg PO BID). She maintained seizure freedom on this regimen for another 4 months, but continued to experience severe mood and behavioral side effects on levetiracetam. With her newborn baby growing, she is able to sleep more continuous-hours at night with less risk of sleep deprivation provoking seizures and therefore the plan is to slowly taper her levetiracetam dosage with eventual goal of return to LTG monotherapy.
Discussion
Valproic acid is historically considered the gold standard medication for treatment of JME. More recently LEV, LTG, TPM, ZNG have been used as first line or adjunctive treatment. 11, [19] [20] [21] [22] It is well known that enzyme-inducing sodium channel blockers (phenytoin, carbamazepine and oxcarbazepine) as well as vigabatrin and gabapentin can aggravate myoclonic seizures in JME. [23] [24] [25] [26] Lamotrigine, a non-enzyme inducing sodium channel blocker, can also cause denovo myoclonus or aggravate existing myoclonic seizures. 27 The effects of lacosamide, a novel non-enzyme inducing sodium channel blocker, on myoclonic seizures are not known. The use of lacosamide as adjunctive treatment of intractable primary generalized epilepsy has been reported in two published abstract, 17, 18 one of which included patients with JME. 17 Lacosamide has also been used as an add-on treatment in a patient with type 1 progressive myoclonic epilepsy, causing a significant reduction in the number of myoclonic events and improved cognition. 28 The ultimate mechanism responsible for ictal myoclonic jerks in JME is thought to be largely similar to cortical myoclonus in progressive myoclonic epilepsies. 29 Our three patients are quite representative of patients that are routinely diagnosed with classic JME in everyday practice of epilepsy. They all had normal cognition, and experienced juvenile onset myoclonic jerks followed by convulsions, additionally one patient experienced absence seizures. They all had normal MRI and classical EEG features of JME. Our three patients were not necessarily intractable. Two had a period of good seizure control on VPA and/or LTG and one was not well controlled on these agents (either as monotherapy or in combination). The patients were started on lacosamide because they could not tolerate or were not willing to try otherAEDs approved for treatment of JME (due to side effect profile). None of the patients experienced worsening of their myoclonus, and in one patient intermittent myoclonic jerks responded to increased dosage of lacosamide. In these three patients, we did not observe any special pharmacodynamic actions causing exacerbation or worsening of their JME.
In conclusion, due to a need for lifelong treatment, the choice of AED in juvenile myoclonic epilepsy is of particular importance. The acute idiosyncratic and chronic dose-related side effects of AEDs can affect patients' quality of life and morbidity, while inappropriately chosen AEDs can aggravate this syndrome and cause pseudo-intractability. The data from our three patients suggest that lacosamide does not necessarily aggravate JME, and in two of the patients it may have been effective in the treatment of JME. Larger studies are needed to further explore the efficacy and role of lacosamide in the treatment of this disorder.
